Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain

Blood

Volumn 113, Issue 18, 2009, Pages 4250-4261

  Gaufin, Thaidra ^a   Gautam, Rajeev ^a   Kasheta, Melissa ^b   Ribeiro, Ruy ^c   Ribka, Erin ^a   Barnes, Mary ^a   Pattison, Melissa ^a   Tatum, Coty ^a   MacFarland, Jeanne ^a   Montefiori, David ^d   Kaur, Amitinder ^b   Pandrea, Ivona ^a,e   Apetrei, Cristian ^a,f  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD79A ANTIGEN; NEUTRALIZING ANTIBODY; RITUXIMAB; CD20 ANTIGEN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG MECHANISM; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; INFECTION CONTROL; INTESTINE; LYMPH NODE; MALE; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MACACA; MONKEY DISEASE; PATHOGENICITY; PHYSIOLOGY; T LYMPHOCYTE; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGENS, CD20; B-LYMPHOCYTES; FLOW CYTOMETRY; IMMUNITY, CELLULAR; IMMUNOENZYME TECHNIQUES; IMMUNOLOGIC FACTORS; INTESTINES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MACACA MULATTA; MALE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 63149158471     PISSN: 00064971     EISSN: 15280020     Source Type: None    
DOI: 10.1182/blood-2008-09-177741     Document Type: Article

References (55)

1. Desrosiers RC. Prospects for an AIDS vaccine. Nat Med. 2004;10:221-223.
2. Staprans SI, Feinberg MB. The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines. Expert Rev Vaccines. 2004;3(4 suppl):S5-S32.
3. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650-4655. (Pubitemid 24183063)
4. Betts MR, Ambrozak DR, Douek DC, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol. 2001;75:11983-11991.
5. Friedrich TC, Valentine LE, Yant LJ, et al. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol. 2007;81:3465-3476.
6. O'Connor DH, Mothe BR, Weinfurter JT, et al. Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J Virol. 2003;77:9029-9040.
7. Shacklett BL, Cox CA, Quigley MF, et al. Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection. J Immunol. 2004;173:641-648.
8. Casimiro DR, Wang F, Schleif WA, et al. Attenuation of simian immunodeficiency virus SIV-mac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol. 2005;79:15547-15555. (Pubitemid 43032336)
9. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med. 2008;205:7-12.
10. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med. 2008;14:617-621.
11. Mascola JR. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine. 2002;20:1922-1925.
12. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001;75:8340-8347.
13. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6:207-210. (Pubitemid 30082367)
14. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000;6:200-206. (Pubitemid 30082366)
15. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med. 2003;9:343-346. (Pubitemid 36362791)
16. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449:101-104. (Pubitemid 47373775)
17. Koff WC, Johnson PR, Watkins DI, et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol. 2006;7:19-23.
18. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307-312.
19. Frost SD, Wrin T, Smith DM, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A. 2005;102:18514-18519. (Pubitemid 43011257)
20. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 2004;303:2019-2022. (Pubitemid 38393277)
21. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100:4144-4149. (Pubitemid 36418171)
22. Crooks ET, Moore PL, Richman D, et al. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies. 2005;14:101-113. (Pubitemid 43748240)
23. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999;283:857-860. (Pubitemid 129501128)
24. Metzner KJ, Jin X, Lee FV, et al. Effects of in vivo CD8+ T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med. 2000;191:1921-1931. (Pubitemid 30390354)
25. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991-998. (Pubitemid 29149355)
26. Miller CJ, Genesca M, Abel K, et al. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol. 2007;81:5024-5035. (Pubitemid 46744414)
27. Schmitz JE, Kuroda MJ, Santra S, et al. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol. 2003;77:2165-2173. (Pubitemid 36110029)
28. Apetrei C, Kaur A, Lerche NW, et al. Molecular epidemiology of SIVsm in US Primate Centers unravels the origin of SIVmac and SIVstm. J Virol. 2005;79:8991-9005.
29. Gautam R, Carter AC, Katz N, et al. In vitro characterization of primary SIVsmm isolates belonging to different lineages: in vitro growth on rhesus macaque cells is not predictive for in vivo replication in rhesus macaques. Virology. 2007;362:257-270.
30. National Research Council. Guide for the care and use of laboratory animals. National Academy Press: Washington, DC; 1996.
31. Knapp LA, Lehmann E, Hennes L, Eberle ME, Watkins DI. High-resolution HLA-DRB typing using denaturing gradient gel electrophoresis and direct sequencing. Tissue Antigens. 1997;50:170-177. (Pubitemid 27326283)
32. Veazey RS, Lifson JD, Pandrea I, Purcell J, Piatak M Jr, Lackner AA. Simian immunodeficiency virus infection in neonatal macaques. J Virol. 2003;77:8783-8792. (Pubitemid 36936090)
33. Pandrea I, Apetrei C, Dufour J, et al. Simian immunodeficiency virus (SIV) SIVagm.sab infection of Caribbean African green monkeys: new model of the study of SIV pathogenesis in natural hosts. J Virol. 2006;80:4858-4867.
34. Pandrea I, Apetrei C, Gordon S, et al. Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood. 2007;109:1069-1076.
35. Pandrea I, Ribeiro RM, Gautam R, et al. Simian immunodeficiency virus SIVagm dynamics in African green monkeys. J Virol. 2008;82:3713-3724.
36. Simon F, Souquiere S, Damond F, et al. Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses. AIDS Res Hum Retroviruses. 2001;17:937-952. (Pubitemid 32881336)
37. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV and SHIV in a luciferase reporter gene assay. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, Coico R, eds. Current Protocols in Immunology. Hoboken, NJ: John Wiley & Sons; 2004.
38. Wang Z, Metcalf B, Ribeiro RM, McClure H, Kaur A. Th-1-type cytotoxic CD8+ T-lymphocyte responses to simian immunodeficiency virus (SIV) are a consistent feature of natural SIV infection in sooty mangabeys. J Virol. 2006;80:2771-2783. (Pubitemid 43346372)
39. Chan KS, Kaur A. Flow cytometric detection of degranulation reveals phenotypic heterogeneity of degranulating CMV-specific CD8+ T lymphocytes in rhesus macaques. J Immunol Methods. 2007;325:20-34. (Pubitemid 47238286)
40. Pinheiro JC, Bates DM. Mixed-effects Models in S and S-Plus. New York, NY: Springer-Verlag; 2002.
41. Bánki Z, Kacani L, Rusert P, et al. Complement dependent trapping of infectious HIV in human lymphoid tissues. AIDS. 2005;19:481-486. (Pubitemid 40515851)
42. Kacani L, Prodinger WM, Sprinzl GM, et al. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol. 2000;74:7997-8002. (Pubitemid 30641644)
43. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med. 2006;12:289-295. (Pubitemid 43355074)
44. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859-870.
45. Vittecoq D, Chevret S, Morand-Joubert L, et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci U S A. 1995;92:1195-1199.
46. Jacobson JM, Colman N, Ostrow NA, et al. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis. 1993;168:298-305. (Pubitemid 23210603)
47. Binley JM, Clas B, Gettie A, et al. Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. Virology. 2000;270:237-249. (Pubitemid 30256556)
48. Florese RH, Van Rompay KK, Aldrich K, et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol. 2006;177:4028-4036. (Pubitemid 44359936)
49. Poignard P, Sabbe R, Picchio GR, et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity. 1999;10:431-438. (Pubitemid 29205479)
50. Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med. 2007;4:e348.
51. Langlois AJ, Desrosiers RC, Lewis MG, et al. Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. J Virol. 1998;72:6950-6955. (Pubitemid 28324023)
52. Means RE, Greenough T, Desrosiers RC. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J Virol. 1997;71:7895-7902. (Pubitemid 27391740)
53. Nowak MA, Lloyd AL, Vasquez GM, et al. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol. 1997;71:7518-7525. (Pubitemid 27391692)
54. Holl V, Peressin M, Decoville T, et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol. 2006;80:6177-6181. (Pubitemid 43849196)
55. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008;28:639-650. (Pubitemid 351636247)